Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 34Melanoma 13Carcinoma, Hepatocellular 13Neoplasm Metastasis 12Lung Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Neoplasms 9Esophageal Neoplasms 9Colorectal Neoplasms 6Esophageal Squamous Cell Carcinoma 5Breast Neoplasms 5Recurrence 4Rectal Neoplasms 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Liver Neoplasms 3Head and Neck Neoplasms 3Cholangiocarcinoma 3Carcinoma, Renal Cell 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Radiation Pneumonitis 2Prostatic Neoplasms 2Pathologic Complete Response 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neuroblastoma 2

Interventions

Carboplatin 7Trastuzumab 6Docetaxel 5pembrolizumab 4Paclitaxel 4Oxaliplatin 4Fluorouracil 4Cytarabine 4Cyclophosphamide 4Azacitidine 4pertuzumab 3Radiotherapy 3Epirubicin 3Cisplatin 3Chemoradiotherapy 3Capecitabine 3venetoclax 2toripalimab 2sargramostim 2olaparib 2durvalumab 2cc-486 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Pemetrexed 2Observation 2Monatide (IMS 3015) 2Metformin 2Leucovorin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Pathologic Complete Response × Immunotherapy × Clear all
NCT07397442 2026-02-11

Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer

Beijing Friendship Hospital

Phase 2 Not yet recruiting
19 enrolled
Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT06811844 2025-07-01

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

The First Affiliated Hospital of Xiamen University

Phase 2 Recruiting
208 enrolled
Head & Neck

Pathologic Complete Response, Nasopharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡